Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
US-2018000824-A1 · Jan 4, 2018 · US
2-pyrimidone analogs as potent antiviral agents against alphaviruses
US11566019B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11566019-B2 |
| Application number | US-202117221666-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 2, 2021 |
| Priority date | Apr 2, 2020 |
| Publication date | Jan 31, 2023 |
| Grant date | Jan 31, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having a structure selected from: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , and a pharmaceutically acceptable carrier. 3. A method for treating a viral infection in a subject, the method comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the viral infection is due to an Alphavirus, thereby treating the viral infection. 4. The method of claim 3 , wherein the Alphavirus is selected from Chikungunya virus (CHIKV), Ross River virus, Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), and Western equine encephalitis (WEEV). 5. The method of claim 3 , wherein the Alphavirus is selected from CHIKV, WEEV, EEEV, and VEEV.
Assignees
Inventors
Classifications
the oxygen-containing ring being six-membered · CPC title
Bridged systems · CPC title
- C07D403/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Sulfur atoms · CPC title
Two or more oxygen atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11566019B2 cover?
- The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of search…
- Who is the assignee on this patent?
- Southern Res Inst, Univ Oregon Health & Science
- What technology area does this patent fall under?
- Primary CPC classification C07D403/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).